© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Quest Diagnostics Incorporated (DGX) stock declined over -0.06%, trading at $238.35 on NYSE, down from the previous close of $238.50. The stock opened at $236.34, fluctuating between $236.34 and $239.38 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 07, 2026 | 236.34 | 239.38 | 236.34 | 238.35 | 568.33K |
| Aug 06, 2026 | 237.66 | 238.88 | 235.32 | 238.50 | 634.3K |
| Aug 05, 2026 | 234.22 | 236.67 | 232.56 | 235.84 | 674.19K |
| Aug 04, 2026 | 231.95 | 234.55 | 229.76 | 233.72 | 876.21K |
| Aug 03, 2026 | 232.84 | 233.44 | 230.54 | 231.95 | 839.18K |
| Jul 31, 2026 | 234.00 | 235.29 | 232.01 | 233.01 | 872.39K |
| Jul 30, 2026 | 230.91 | 235.61 | 229.01 | 234.30 | 926.43K |
| Jul 29, 2026 | 235.11 | 237.84 | 233.00 | 235.22 | 964.44K |
| Jul 28, 2026 | 235.18 | 240.13 | 233.98 | 235.94 | 1.59M |
| Jul 27, 2026 | 225.95 | 231.95 | 224.97 | 231.84 | 1.14M |
| Jul 24, 2026 | 228.00 | 233.21 | 223.42 | 227.86 | 1.54M |
| Jul 23, 2026 | 228.09 | 237.78 | 220.00 | 227.90 | 3.75M |
| Jul 22, 2026 | 207.13 | 212.30 | 205.41 | 209.83 | 1.83M |
| Jul 21, 2026 | 206.16 | 208.01 | 204.10 | 206.84 | 684.43K |
| Jul 20, 2026 | 208.61 | 211.00 | 205.61 | 207.66 | 822.63K |
| Jul 17, 2026 | 210.95 | 214.40 | 209.41 | 210.68 | 955.45K |
| Jul 16, 2026 | 201.00 | 209.56 | 201.00 | 209.41 | 980.88K |
| Jul 15, 2026 | 204.68 | 206.41 | 201.12 | 201.77 | 1.19M |
| Jul 14, 2026 | 202.80 | 208.52 | 201.13 | 206.00 | 865.69K |
| Jul 13, 2026 | 207.48 | 210.76 | 207.01 | 207.35 | 567.12K |
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
| Employees | 57000 |
| Beta | 0.57 |
| Sales or Revenue | $9.87B |
| 5Y Sales Change% | 0.492% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |